UP!
Alder Biopharmaceuticals is a pharmaceutical development company based in Bothell, Washington. Alder specializes in therapeutic monoclonal antibodies. The company was founded by Randall C. Schatzman, John A. Latham, and Mark J. Litton in 2004. The CEO is Dr. Randy Schatzman. Alder went public in May 2014.
Their best known drug is the monoclonal antibody eptinezumab, which is now in its second phase III trial for migraine prevention. They have a second monoclonal antibody drug for migraine, ALD-1910, currently in pre-clinical development. Alder licensed clazakizumab, previously ALD-518, an anti-IL-6 monoclonal antibody to Vitaeris, Inc. for worldwide marketing.
| 2016-06-30 | Reiterated Rating | Jefferies Group | Buy | |
| 2016-06-09 | Reiterated Rating | Jefferies Group | Buy | $61.00 |
| 2016-04-30 | Reiterated Rating | Brean Capital | Buy | |
| 2016-04-21 | Initiated Coverage | Wells Fargo | Outperform | |
| 2016-04-21 | Initiated Coverage | Wells Fargo & Co. | Outperform | |
| 2016-04-20 | Initiated Coverage | Brean Capital | Positive to Buy | $45.00 |
| 2016-03-29 | Reiterated Rating | Jefferies Group | Buy | $62.00 |
| 2016-03-29 | Reiterated Rating | Credit Suisse | Outperform | $40.00 |
| 2016-03-29 | Reiterated Rating | Leerink Swann | Outperform | |
| 2016-03-29 | Reiterated Rating | Credit Suisse Group AG | Outperform | $40.00 |
| 2016-02-15 | Reiterated Rating | Jefferies | Buy | $58.00 |
| 2016-02-15 | Reiterated Rating | Jefferies Group | Buy | $58.00 |
| 2016-02-13 | Reiterated Rating | Jefferies Group | Buy | |
| 2016-02-01 | Reiterated Rating | Leerink Swann | Buy | |
| 2015-10-15 | Lower Price Target | Jefferies Group | Buy | $58.00 |
| 2015-09-08 | Initiated Coverage | Jefferies Group | Buy | $72.00 |
| 2015-08-07 | Reiterated Rating | Leerink Swann | Buy | |
| 2015-08-06 | Boost Price Target | Leerink Swann | Outperform | $62.00 |
| 2015-06-25 | Reiterated Rating | Credit Suisse | Buy | |
| 2015-06-24 | Initiated Coverage | Credit Suisse | Outperform | $50.00 |
| 2015-05-05 | Reiterated Rating | Credit Suisse | Outperform | $36.00 |
| 2015-03-05 | Boost Price Target | Leerink Swann | Outperform | $24.00 to $31.00 |
| 2014-12-17 | Boost Price Target | Credit Suisse | Outperform | $19.00 to $34.00 |
| 2014-09-02 | Lower Price Target | Leerink Swann | $26.00 to $24.00 | |
| 2014-06-11 | Initiated Coverage | Sanford C. Bernstein | Outperform | $30.00 |
| 2014-06-02 | Initiated Coverage | Credit Suisse | Outperform | $20.00 |
| 2014-06-02 | Initiated Coverage | Wells Fargo & Co. | Outperform | |
| 2014-06-02 | Initiated Coverage | Leerink Swann | Outperform | $26.00 |
| 2014-06-02 | Initiated Coverage | Wells Fargo | Outperform |
| 2016-06-30 | Reiterated Rating | Jefferies Group | Buy | |
| 2016-06-09 | Reiterated Rating | Jefferies Group | Buy | $61.00 |
| 2016-04-30 | Reiterated Rating | Brean Capital | Buy | |
| 2016-04-21 | Initiated Coverage | Wells Fargo | Outperform | |
| 2016-04-21 | Initiated Coverage | Wells Fargo & Co. | Outperform |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In ALDR 16 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| JANUS CAPITAL MANAGEMENT LLC | 5.17M |
| BlackRock Fund Advisors | 2.13M |
| BlackRock Institutional Trust Company, N.A. | 1.25M |
| TIAA CREF INVESTMENT MANAGEMENT LLC | 0.75M |
| BLACKROCK ADVISORS LLC | 0.26M |
| BlackRock Investment Management, LLC | 0.18M |
| TEACHERS ADVISORS INC | 0.13M |
| Apex Capital Management | 0.12M |
| EverPoint Asset Management, LLC | 0.11M |
| MANAGED ACCOUNT ADVISORS LLC | 73715 |
| KCG Holdings, Inc. | 53453 |
| BlackRock Group LTD | 52128 |
| CORNERSTONE CAPITAL MANAGEMENT HOLDINGS LLC. | 41120 |
| Numeric Investors LLC | 14800 |
| Jump Trading, LLC | 14500 |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| Ventures West 8 Limited Partnership | 11.26% (3469528) | ALDR / |
| Novo A/S SEE REMARKS | 10.39% (3201183) | AKBA / ALDR / CRVS / FLXN / INGN / LPTN / OPHT / OTIC / RETA / RGDO / ZSPH / |
| PAKIANATHAN DEEPIKA | 9.21% (2838532) | ALDR / ALXA / CALA / KPTI / OMED / |
| Delphi Management Partners VII, L.L.C. | 9.21% (2838532) | ALDR / |
| TPG Group Holdings (SBS) Advisors, Inc. | 8.08% (2488533) | AERI / ALDR / CDNA / CZR / EPRS / FSL / GPK / IMS / LPLA / MGNX / NCLH / NTI / OTIC / PKY / Q / ROKA / SABR / SCAI / SUP / TIPT / TMHC / TNDM / VCYT / ZMH / |
| Davidson Aaron | 1.68% (516395) | ALDR / OCRX / |
| H.I.G. Venture Partners II, L.P. | 1.68% (516395) | ALDR / |
| DOW STEPHEN M | 1.00% (307190) | ALDR / CTXS / CYTK / |
| Latham John A Chief Scientific Officer | 0.79% (243208) | ALDR / |
| Schatzman Randall C President and CEO | 0.47% (145172) | ALDR / |
| Litton Mark James Chief Business Officer | 0.38% (116451) | ALDR / |
| SIEGALL CLAY B | 0.10% (31714) | ALDR / SGEN / |
| Benedict Larry Sr. VP Finance | 0.10% (30989) | ALDR / |
| Montgomery Alan Bruce | 0.03% (9628) | ALDR / XNCR / |
| YARNO WENDY L | 0.02% (5000) | ALDR / DRTX / INO / MDVN / PETX / STJ / |
| JAGGERS JOHN V | 0.01% (4458) | ALDR / CPST / |
| Bucher James B Sr. VP & General Counsel | 0.01% (1623) | ALDR / |
UM